BioAtla (NASDAQ:BCAB) Receives Neutral Rating from HC Wainwright

BioAtla (NASDAQ:BCAB)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports.

BioAtla Stock Down 4.9 %

BioAtla stock opened at $0.37 on Monday. The business has a 50 day moving average price of $0.40 and a two-hundred day moving average price of $1.12. BioAtla has a 12 month low of $0.24 and a 12 month high of $4.02. The stock has a market cap of $18.05 million, a price-to-earnings ratio of -0.22 and a beta of 1.19.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. On average, analysts expect that BioAtla will post -1.46 earnings per share for the current fiscal year.

Institutional Trading of BioAtla

Several institutional investors have recently made changes to their positions in the business. XTX Topco Ltd lifted its stake in BioAtla by 7.2% during the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after purchasing an additional 10,384 shares during the period. Magnus Financial Group LLC acquired a new position in shares of BioAtla in the 4th quarter worth approximately $28,000. Two Sigma Investments LP lifted its position in shares of BioAtla by 84.0% during the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after buying an additional 61,725 shares during the period. Jane Street Group LLC grew its position in BioAtla by 204.1% in the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after acquiring an additional 100,204 shares during the period. Finally, Renaissance Technologies LLC raised its stake in BioAtla by 62.2% during the fourth quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock worth $490,000 after acquiring an additional 318,196 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.